Pregled bibliografske jedinice broj: 1033507
Vemurafenib and cobimetinib ‐ induced toxic epidermal necrolysis in a patient with metastatic melanoma
Vemurafenib and cobimetinib ‐ induced toxic epidermal necrolysis in a patient with metastatic melanoma // Dermatologic therapy, 33 (2019), 1; e13174, 1 doi:10.1111/dth.13174 (međunarodna recenzija, kratko priopcenje, znanstveni)
CROSBI ID: 1033507 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Vemurafenib and cobimetinib ‐ induced toxic epidermal
necrolysis in a patient with metastatic melanoma
Autori
Poduje, Sanja ; Marić Brozić, Jasmina ; Prkačin, Ivana ; Delaš Aždajić, Marija ; Goren, Andy
Izvornik
Dermatologic therapy (1396-0296) 33
(2019), 1;
E13174, 1
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, kratko priopcenje, znanstveni
Ključne riječi
combined target therapy ; toxic epidermal necrolysis ; metastatic melanoma
Sažetak
Combination therapy in the treatment of metastatic melanoma has been associated with more durable response rate compared to monotherapy. However, previous studies have shown that combined target therapy commonly causes a wide spectrum of adverse events. These adverse reactions are usually manageable, however, it is always necessary to compare drug efficacy with its potential adverse effects. Toxic epidermal necrolysis represents severe mucocutaneous reaction, usually triggered by medications and characterized by extensive necrosis and detachment of the epidermis. Here we present a first case of toxic epidermal necrolysis induced by combined target therapy (vemurafenib plus cobimetinib). The case was observed in a young patient with BRAF mutant melanoma who was started on first‐line metastatic immunotherapy with pembrolisumab.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
KBC "Sestre Milosrdnice"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE